OUP user menu

BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts

Thomas Krieg, Yanping Liu, Thomas Rütz, Carmen Methner, Xi-Ming Yang, Turhan Dost, Stephan B. Felix, Johannes-Peter Stasch, Michael V. Cohen, James M. Downey
DOI: http://dx.doi.org/10.1093/eurheartj/ehp143 1607-1613 First published online: 30 April 2009


Aims BAY 58-2667 (BAY-58) directly activates soluble guanylyl cyclase without tolerance in a nitric oxide (NO)-independent manner, and its haemodynamic effect is similar to that of nitroglycerin. We tested whether BAY-58 could make both rabbit and rat hearts resistant to infarction when given at the end of an ischaemic insult.

Methods and results All hearts were exposed to 30 min regional ischaemia followed by 120-(isolated hearts) or 180-(in situ hearts) min reperfusion. BAY-58 (1–50 nM) infused for 60 min starting 5 min before reperfusion significantly reduced infarction from 33.0 ± 3.2% in control isolated rabbit hearts to 9.5–12.7% (P < 0.05). In a more clinically relevant in situ rabbit model, infarct size was similarly reduced with a loading dose of 53.6 µg/kg followed by a 60 min infusion of 1.25 µg/kg/min (41.1 ± 3.1% infarction in control hearts to 16.0 ± 4.4% in treated hearts, P < 0.05). BAY-58 similarly decreased infarction in the isolated rat heart, and protection was abolished by co-treatment with a protein kinase G (PKG) antagonist, or a mitochondrial KATP channel antagonist. Conversely, Nω-nitro-L-arginine-methyl-ester-hydrochloride, a NO-synthase inhibitor, failed to block BAY-58's ability to decrease infarction, consistent with the latter's putative NO-independent activation of PKG. Finally, BAY-58 increased myocardial cGMP content in reperfused hearts while cAMP was unchanged.

Conclusion When applied at reperfusion, BAY-58 is an effective cardioprotective agent with a mechanism similar to that of ischaemic pre-conditioning and, hence, should be a candidate for treatment of acute myocardial infarction in man.

  • BAY 58-2667
  • Cardioprotection
  • Guanylyl cyclase
  • Protein kinase G
  • Reperfusion


The intracellular second messenger cyclic guanosine 3′,5′-monophosphate (cGMP) plays a role in various physiological processes. cGMP is generated by two distinct enzymes: the cytoplasmatic soluble guanylyl cyclase (sGC), a heterodimer consisting of α- and β-subunits, and the membrane-bound particulate guanylyl cyclase. While sGC acts as a receptor for the biological messenger nitric oxide (NO), particulate guanylyl cyclase is the receptor for extracellular natriuretic peptides. cGMP effectors include the cGMP-dependent protein kinase [protein kinase G (PKG)], cGMP-modulated cation channels, and cGMP-regulated phosphodiesterases (PDEs).

In recent years, there has been accumulating evidence that cGMP and its downstream target PKG play crucial roles in the survival signalling of pre- and post-conditioning.1 While pre-conditioning leads to infarct size reduction following several short ischaemic cycles preceding a lethal ischaemic insult,2 post-conditioning represents a comparable phenomenon in which brief cycles of coronary flow interruption are applied after the prolonged ischaemic period.3 Pharmacological post-conditioning can also be accomplished by giving an agent that activates ischaemic post-conditioning's pro-survival pathways at the time of reperfusion. Because of their obvious clinical potential in the treatment of acute myocardial infarction in man, both ischaemic and pharmacological post-conditioning have received much attention in recent years. While clinical trials with ischaemic post-conditioning are quite encouraging,4 the ideal pharmacological post-conditioning agent has yet to be identified.5

The signalling pathway of ischaemic pre-conditioning is complex and can be divided into two phases: a pre-ischaemic trigger phase and a post-ischaemic mediator phase.5 During the trigger phase, ischaemic myocardium releases agonists to Gi protein-coupled receptors, including adenosine, bradykinin, and opioids. Although there are some differences between signalling triggered by these three agonists, the target is activation of protein kinase C (PKC). For bradykinin and opioids, the signalling involves activation of nitric oxide synthase (NOS) with subsequent activation of PKG. Protein kinase G opens mitochondrial KATP channels (mKATP) leading to increased production of reactive oxygen species which in turn activate PKC. Signalling during reperfusion after the index ischaemia is less well understood, but generally involves activation of survival kinases, Akt, and extracellular regulated kinase, by PKC which inhibits formation of the mitochondrial permeability transition pore during the early minutes of reperfusion resulting in prevention of cell necrosis.

The NO/GC/cGMP/PKG signalling cascade has been shown to be an important sequence in both pre- and post-conditioning. Nitric oxide and PKG are central to bradykinin's ability to pre-condition the heart,6 and these same components are needed in ischaemic pre-conditioning.7 Activating these elements at reperfusion proved to be equally protective. For example, it could be shown that activation of particulate guanylyl cyclase by atrial natriuretic peptide8 or B-type natriuretic peptide9 or direct activation of PKG8 at reperfusion all result in profound protection comparable to that seen in pre-conditioning. Furthermore, activation of PKG by increasing cGMP levels as a result of PDE Type 5 inhibition at reperfusion also caused a profound anti-infarct effect.10,11 It is less clear how well direct administration of NO donors, such as SNAP or nitroglycerin, at reperfusion limit infarction.11 That may be because haemodynamic effects limit the dose that can be given.

Since NO has undesirable effects independent of PKG activation, these unwanted effects might be eliminated if sGC could be selectively and exclusively activated. In the present study, we tested a novel NO- and haem-independent activator of sGC, BAY 58-2667 (hereafter referred to as BAY-58).12 BAY-58 is currently being evaluated for the treatment of chronic heart failure in early clinical trials and appears to be well tolerated. Its NO independence may make it an ideal candidate for a pharmacological approach to reduce infarct size at reperfusion during an acute myocardial infarction.


Infarct size studies were conducted in Mobile, Alabama and Greifswald, Germany. Rabbits were used in Mobile, whereas rats were studied in Greifswald. These studies were performed in accordance with The Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC, 1996). The experimental protocols used in the rat experiments were approved by the local authorities of the state of Mecklenburg-Vorpommern (LALLF M-V/TSD/7221.3-2.3-014/08), and protocols in rabbits by the IACUC committee at the University of South Alabama.

Isolated rabbit heart

Briefly, New Zealand white rabbits were anesthetized with pentobarbital sodium (30 mg/kg i.v.) and ventilated with 100% oxygen. After a left thoracotomy in the fourth interspace, a suture was passed around a major anterior epicardial coronary arterial branch coursing towards the apex. The heart was excised and perfused on a Langendorff apparatus with Krebs–Henseleit bicarbonate buffer containing (mM) 118.5 NaCl, 24.8 NaHCO3, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.5 CaCl2, and 10 glucose, and bubbled with 95% O2/5% CO2 to a pH of 7.35–7.45 at 38°C. A fluid-filled latex balloon measured pressure in the left ventricle as the heart beat spontaneously and isometrically.

Experimental protocol

Hearts of four experimental groups were studied. The snared coronary branch was occluded for 30-min and reperfused for 2 h in all groups. In the control group, no other treatment was given. In the drug-treated groups, BAY-58 was added to the perfusate for 1 h starting 5 min prior to reperfusion to yield concentrations of either 50, 10, or 1 nM in the buffer perfusate.

Measurement of risk zone and infarct size

At the end of the experiments, the coronary artery was re-occluded, and fluorescent microspheres were infused to demarcate the ischaemic zone. Hearts were weighed, frozen, and then cut into 2 mm thick transverse slices. The slices were incubated in 1% triphenyltetrazolium chloride (TTC) in sodium phosphate buffer. Triphenyltetrazolium chloride stains the non-infarcted myocardium brick-red indicating the presence of dehydrogenase enzymes. The slices were then immersed in 10% formalin to enhance the contrast between stained (viable) and unstained (necrotic) tissue. After illumination with UV light, the risk zone was identified as the non-fluorescent region. The areas of infarct and risk zone were determined by planimetry of each slice and volumes were calculated by multiplying each area by the slice thickness and summing them for each heart. Infarct size was expressed as a percentage of the risk zone.

In situ rabbit heart

New Zealand white rabbits were anesthetized as above and throughout the experiment, additional anaesthesia was administered as needed (∼4 mg/kg pentobarbital every 15 min). A heating pad maintained rectal temperature between 38.5 and 39.5°C. Animals were intubated through a tracheotomy and ventilated with 100% O2. Arterial pH, pO2, and pCO2 were measured with a blood gas analyzer. Respiratory rate was adjusted to keep pH between 7.35 and 7.45. In this preparation, arterial pO2 averages 180–200 mmHg and pCO2 25–30 mmHg. A PE 50 catheter filled with heparinized saline (10 U/mL) was placed in the right carotid artery to monitor arterial blood pressure and to measure arterial pH and gases. To administer drugs, a butterfly needle was placed in an ear vein.

After a left thoracotomy in the fourth interspace, a prominent branch of the left coronary artery was surrounded with a suture (2-0 silk) to form a snare. The rabbits were allowed to stabilize for 15 min after surgery before the protocols were begun. In all cases, the coronary branch was occluded for 30 min and reperfused for 3 h.

Experimental protocol

Four experimental groups were studied. Control hearts had only the index occlusion followed by reperfusion. In drug-treated animals, BAY-58 was started 5 min before the onset of reperfusion. BAY-58 was given as a bolus of 53.6 µg/kg followed by a 60 min infusion of either 5.36 or 1.25 µg/kg/min. The doses and schedules were based on pharmacokinetic data from laboratory animals provided by the manufacturer (volume of distribution approximates whole body water and t½ is 30 min). Finally, we tested the vehicle which was a mixture of dimethyl sulfoxide (DMSO), polyethylene glycol, and water.

Measurement of risk zone and infarct size

After completion of the experiment, all hearts were excised and the aortic root was perfused with 0.9% saline. The coronary artery was re-occluded, and infarct size was determined as outlined above.

Isolated rat heart

We wanted to extend our study to a second species so we chose the rat. Hearts from male Wistar rats were quickly excised and mounted on a Langendorff apparatus, as described for the isolated rabbit hearts above. We decided to use the isolated rat hearts for the mechanistic studies for two reasons. First, we wanted a crystalloid-perfused preparation so we could control the dose of the inhibitors as tissue concentration of drugs in in situ preparations are unknown due to uncertainties in their volume of distribution, half life, and protein binding. Secondly, the smaller coronary flow rate reduces the cost of inhibitor drugs such as KT5823 which are quite expensive.

Experimental protocol

Five groups of hearts were subjected to regional ischaemia for 30 min followed by 2 h of reperfusion. Control hearts were subjected to ischaemia and reperfusion with no treatment. One group of hearts was treated with 50 nM BAY-58 starting 5 min prior to reperfusion and continuing for the entire reperfusion period. In the remaining three groups, one of three inhibitors was co-infused with BAY-58. Either the NOS inhibitor Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME, 200 µM), the mKATP channel blocker 5-hydroxydecanoate (5-HD, 100 µM), or KT5823 (1 µM), a PKG inhibitor, was added to the perfusate. At the end of reperfusion, infarct size was determined as described above for isolated rabbit hearts.

Radioimmunoassay for cAMP and cGMP

Isolated rat hearts were perfused on a Langendorff apparatus as described above. A transmural biopsy of the left ventricle was obtained after 30 min of global ischaemia followed by 10 min of reperfusion and immediately frozen in liquid nitrogen. Two groups were studied: control hearts received no treatment while the second group was treated with 50 nM BAY-58 during reperfusion. The frozen tissue pieces were weighed and resuspended in 300 µL homogenization buffer containing 1 mM IBMX. After sonication and spinning for 30 min at 10 000 rpm, the supernatant was used for the measurements. Cyclic nucleotide content was measured with a commercial radioimmunoassay kit (IBL-Transatlantic Corp., Toronto, Canada) according to the manufacturer's high sensitivity protocol. The lower limit of detection was 5 fmol. Each sample was analysed twice.


BAY 58-2667 was kindly provided by Bayer HealthCare GmbH, Wuppertal, Germany. KT5823 was obtained from Alexis Pharma, Lörrach, Germany. All other chemicals were from Sigma-Aldrich Chemical Co. For rabbit studies, BAY-58 was dissolved in the company vehicle of DMSO, polyethylene glycol, and water. For rat studies, BAY-58 and KT5823 were dissolved in DMSO before being diluted in buffer resulting in a DMSO concentration of less than 0.01%. L-NAME and 5-HD were diluted directly in Krebs–Henseleit buffer.


Data are presented as means ± SEM. Differences in infarct size and baseline haemodynamic variables among groups were compared by one-way ANOVA with Tukey's post hoc testing. Temporal differences in blood pressure measurements in in situ rabbit preparations for the three groups were first compared by two-way ANOVA for repeated measures. When group differences were significant, data at each time point were compared with unpaired t-test with Bonferroni correction for multiple comparisons. Differences in slope of regression lines were evaluated with ANCOVA. A value of P < 0.05 was considered significant.


Isolated rabbit hearts

There were no significant differences in heart rate or developed pressure at baseline among the experimental groups (data not shown). As expected, developed pressure was reduced during coronary occlusion, and only partially recovered after reperfusion. Hearts treated with BAY-58 showed a significantly higher coronary flow at 30 min of reperfusion.

As shown in Figure 1, BAY-58 reduced infarct size from 33.0 ± 3.2% in the control group to 9.5 ± 1.5% for 50 nM, 11.2 ± 1.5% for 10 nM, and 12.7 ± 2.8% for 1 nM. Since all doses tested showed significant protection (P < 0.05 vs. control), we could not determine an EC50 which must be in the picomolar range.

Figure 1

The effect of different concentrations of BAY-58 at reperfusion on infarct size in isolated rabbit hearts expressed as a percentage of the risk zone. Open symbols represent individual experiments and closed symbols the group means. Ischaemic zone sizes for the four groups (from left to right) were 1.29 ± 0.09, 1.28 ± 0.12, 1.09 ± 0.07, and 1.17 ± 0.06 cm2, respectively (P = n.s.). Infusion of BAY-58 during reperfusion was protective even at a concentration of 1 nM. *P < 0.001 vs. control.

In situ rabbit hearts

No group differences in systolic and diastolic pressure, mean arterial pressure, or heart rate were observed at baseline. At the end of reperfusion, no difference was seen between the groups. Figure 2 shows mean blood pressure data. Blood pressure declined mildly and comparably during coronary occlusion in all groups. In rabbits treated with the low-dose infusion of BAY-58, there was a trend toward lower arterial blood pressure during drug infusion, but it was not significantly different than that seen in vehicle-treated animals. The decline in rabbits treated with the higher dose of BAY-58 was more noticeable and became significant following discontinuation of the infusion. Although hypotension persisted to the end of the experiment in these animals, the difference in mean blood pressure after 3 h of reperfusion compared with vehicle-treated hearts was no longer significant. We decided on the lower infusion rate after computer modelling revealed that an infusion of only 1.25 µg/kg/min would be needed to maintain the plasma concentration established by the 53.6 µg/kg loading dose.

Figure 2

The effect on mean blood pressure of two different maintenance doses of BAY-58 in in situ rabbit hearts. Both protocols, high (53.6 µg/kg bolus 5 min prior to reperfusion followed by a 1 h infusion of 5.36 µg/kg/min) as well as low (53.6 µg/kg bolus followed by 1.25 µg/kg/min infusion) infusion, resulted in a mild trend for reduction in blood pressure during drug infusion compared with vehicle-treated group, although changes were not significant. Mild hypotension persisted in animals treated with high infusion of BAY-58. *P < 0.05 with Bonferroni correction vs. vehicle-treated rabbits.

BAY-58 was given as a loading dose followed by an infusion designed to maintain an elevated plasma concentration. At the end of drug infusion, plasma concentration of BAY-58 in rabbits was 318.1 ± 25.9 nM in the high-dose and 65.6 ± 3.45 nM in the low-dose regimen. Thus, even the reduced infusion rate of BAY-58 achieved plasma concentrations well above the protective range identified in the isolated heart suggesting that much lower doses should still be protective. In the BAY-58 hearts receiving the 1.25 µg/kg/min infusion, there was a significant reduction of infarct size from 41.1 ± 3.1% of the risk zone in the control group to 16.0 ± 4.4% (P < 0.05 vs. control) (Figure 3). Although the group treated with the high infusion rate suffered from hypotension, there was also significant protection (P < 0.05). The vehicle used to dissolve BAY-58 had no effect on infarct size (40.6 ± 2.2%, P = n.s.). When infarct size is plotted against risk zone volume for the four groups, it is obvious that the regression lines for the two treatment groups are significantly displaced downwards (P < 0.05) (Figure 4).

Figure 3

The effect of BAY-58 on infarct size in open chest in situ rabbit hearts. Both infusion regimens (high = 5.36 µg/min/kg, and low = 1.25 µg/min/kg) following a bolus of 53.6 µg/kg 5 min prior to reperfusion are equally protective. Ischaemic zone sizes for the four groups (from left to right) were 1.25 ± 0.15, 1.58 ± 0.08, 1.35 ± 0.16, and 1.41 ± 0.07 cm2, respectively (P = ns.). *P < 0.001 vs. control.

Figure 4

Absolute infarct size plotted against absolute risk zone volume. Regression lines for both high and low infusion rates of BAY-58 are significantly different from the control and vehicle-treated groups (P < 0.05).

Isolated rat hearts

We chose to do the mechanistic studies of BAY-58's protective effect in isolated rat hearts because its lower coronary flow rate would greatly reduce the cost of materials. The results are summarized in Figure 5. As expected, BAY-58 at a concentration of 50 nM given at reperfusion reduced infarct size from 34.6 ± 3.4% of the risk zone in the control group to 11.1 ± 3.5% (P < 0.001 vs. control). Co-administration of the NOS inhibitor L-NAME failed to block BAY-58's protection (15.4 ± 3.0% infarction, P < 0.001 vs. control and P = n.s. vs. BAY-58), indicating an NO-independent mechanism. On the other hand, KT5823 as well as 5-HD abolished protection (29.8 ± 1.8 and 29.4 ± 2.7% infarction, resp., P = n.s. vs. control), indicating that the effect of BAY-58 occurred upstream of both PKG and the opening of mKATP. Neither L-NAME,9 KT5823,10 nor 5-HD13 alone have any effect on infarct size in untreated isolated rat hearts when given at reperfusion.

Figure 5

Infarct size as a percentage of risk zone for individual hearts and group means with SEM. The protective effect of 50 nM BAY-58 was blocked by co-administration of either KT5823 or 5-hydroxydecanoate (5-HD), suggesting a role for PKG and the mitochondrial KATP channel, while the NOS inhibitor Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) had no effect on BAY's protective properties, supporting a NO-independent effect of BAY-58. Ischaemic zone sizes for the five groups (from left to right) were 0.126 ± 0.015, 0.145 ± 0.019, 0.114 ± 0.015, 0.144 ± 0.014, and 0.151 ± 0.020 cm2, respectively (P = n.s.). *P < 0.001 vs. control.

Measurement of cyclic nucleotides

The cyclic nucleotides cAMP and cGMP were measured in biopsies of isolated rat hearts undergoing 30 min of global ischaemia and 10 min of reperfusion. There was no difference between the cAMP levels in hearts treated with BAY-58 at reperfusion and the control hearts (0.11 ± 0.018 vs. 0.11 ± 0.014 pmol/mg wet weight), whereas BAY-58 at reperfusion caused a significant increase in cGMP from 0.14 ± 0.058 fmol/mg wet weight in the untreated controls to 4.12 ± 0.81 fmol/mg (P = 0.0014) (Figure 6).

Figure 6

Mean ± SEM of cAMP and cGMP in left ventricular biopsies of isolated rat hearts subjected to 30 min of global ischaemia and 10 min of reperfusion. While a BAY-58 infusion throughout reperfusion had no effect on cAMP levels, it caused a significant increase in cGMP content compared with untreated controls. *P = 0.0014 vs. control.


An intervention that limits myocardial infarction when administered just before reperfusion has great clinical appeal. This investigation examined the efficacy of the novel NO-independent sGC activator BAY-58 which is currently in early clinical testing for the long-term treatment of heart failure. BAY-58 dramatically decreased infarction in both isolated and in situ rabbit hearts as well as isolated rat hearts when administered just prior to reperfusion. Although direct sGC activators including BAY-58 have been reported to reduce cardiac preload and afterload in an animal model of congestive heart failure,14 reverse pulmonary hypertension,15 and attenuate vascular atherosclerosis and restenosis, liver cirrhosis, and renal fibrosis,16 our study is, to our knowledge, the first to suggest that they could also be clinically relevant cardioprotectants.

Guanylyl cyclase generates cGMP which in turn activates PKG and indeed BAY-58 raised the cGMP content in ventricular tissue. BAY-58's protection was abolished by the PKG inhibitor KT5823 indicating that PKG was indeed responsible for the protection. Previous studies have shown that activation of PKG opens mKATP,17 and this mechanism was confirmed when 5-HD, a putatively selective mKATP antagonist, blocked BAY-58's protection. Thus, BAY-58 likely protects by activating PKG and opening mKATP as seen in ischaemic pre-conditioning. Recent studies reveal that a direct PKG activator given at reperfusion also protects against infarction.18 The sequence of signalling was found to be opening of mKATP, generation of ROS, and activation of PKC. Re-introduction of oxygen during reperfusion would provide fuel for the generation of the reactive oxygen species and the subsequent activation of PKC at reperfusion would lead to activation of the survival kinases.

BAY-58 was recently discovered to activate a NO- and haem-independent regulatory site on sGC in the region of the amino acids 371 (α-subunit) and 231–310 (β-subunit). Concentrations of BAY-58 as low as 1 nM activate sGC sufficiently to yield a biologically important increase in cGMP.12 In agreement, we observed an infarct reducing effect of BAY-58 at a concentration of as little as 1 nM in the isolated rabbit heart. We did not test concentrations below 1 nM as our in vivo studies revealed that a plasma concentration of 65 nM was already low enough to avoid haemodynamic effects. The NOS inhibitor L-NAME was not able to block BAY-58's protection, consistent with the latter's NO-independent activation of PKG.

Activated sGC is known to generate cGMP which in turn has various physiological effects through its downstream effector, PKG. In the present study, BAY-58 increased cGMP in reperfused cardiac tissue, but had no effect on cAMP. Because there is extensive cross-talk between cGMP and cAMP at the level of the PDEs,19 we cannot exclude some role for cAMP, but increased cGMP seems to be the most likely factor causing BAY-58's anti-infarct effect. This was supported by our finding that the PKG inhibitor KT5823 abolished BAY-58's protection in isolated rat hearts. Although there are some concerns about the selectivity of KT5823, we are not aware of a more suitable PKG inhibitor that we could have used. Unfortunately, there is no current way to directly assay for PKG activity in a tissue sample as activity depends on the amount of cGMP added to the assay mixture which would be unrelated to that in the tissue. Phosphorylation of the protein VASP has been used as a reporter for PKG activity, but unfortunately cardiomyocytes do not express VASP. Thus, cGMP concentration is currently the best indicator of PKG activation. Although we considered blocking the cAMP-dependent kinase, PKA, with the widely used inhibitor H89, this strategy is not suitable for the present model since H89 has cardioprotective properties which appear to be unrelated to PKA inhibition.20

We have reported that activation of PKG leads to opening of mKATP, and this event is thought to be an important step in pre-conditioning's trigger pathway.7 When the cell-permeant cGMP analog 8-(4-chlorophenylthio)-guanosine 3′,5′-cyclic monophosphate was administered to rabbit hearts just before reperfusion, it protected against infarction and that protection could be prevented by two blockers of mKATP, 5-HD, and glibenclamide,18 suggesting that the opening of mKATP by PKG can protect at reperfusion as well. We could also block the protective effects of BAY-58 with 5-HD, suggesting again that PKG and mKATP are in series in the present protective pathway. Clearly, further investigations are necessary to clarify the exact role played by the channel. Finally, it must be remembered that there has been some criticism about the specificity of 5-HD as an antagonist of mKATP.21

PKG dilates vascular smooth muscle. We, therefore, were concerned that it might not be possible to protect the heart without an unacceptable level of peripheral dilation. The haemodynamic effect of the BAY infusion shown in Figure 2 turned out to be only transient during drug infusion and also very mild in the group receiving the lower infusion rate of 1.25 µg/kg/min. BAY-58 proved to be protective in an in situ rabbit heart model with only modest hypotension, and the decline in blood pressure in animals treated with the low dose infusion was not significant. Since our low infusion rate protocol still produced plasma levels of BAY-58 well above the very protective dose of 1 nM used in isolated hearts, it should be possible to preserve cardioprotection while substantially decreasing the loading bolus and maintenance infusion doses thus eliminating any tendency to produce hypotension.

In past studies, protection afforded at reperfusion is critically dependent on the timing of the intervention and delaying the onset of a post-conditioning stimulus, either pharmacological22 or ischaemic,23 sometimes for as little as 1 min, leads to a loss of protection. We gave a bolus of BAY-58 5 min before reperfusion to increase blood levels quickly so that blood entering the ischaemic zone with the onset of reperfusion would have a high concentration of drug. Based on the pathways involved, BAY-58 most likely activates the pre-conditioning mechanism which protects by preventing destructive mitochondrial permeability transition pores from forming in the first minutes of reperfusion.24 Early treatment would be required to prevent pore formation. We did not test whether delaying the loading dose until a minute or two after reperfusion would cause a loss of protection, but in our pilot studies we did find that infusions without the loading dose were not protective (data not shown). That failure probably was because plasma levels were not in a protective range during the first critical moments of reperfusion. It is not known whether the infusion had to be maintained for a full hour, but our pilot data demonstrated that the loading dose alone was not protective either (data not shown). AMP 579, a drug that also protects at reperfusion by activating the pre-conditioning pathways did require a full hour of infusion to protect. Stopping the AMP579 infusion after only 30 min led to the loss of protection.22

The present data indicate that BAY-58 is highly protective to the ischaemic heart in the clinically relevant scenario in which its administration begins just prior to reperfusion. Infusion of BAY-58 leads to increased levels of cGMP in cardiac tissue, and the protection is independent of NO, but is dependent on both PKG and mKATP. In a rabbit in situ model, low dose intravenous BAY-58 elicits an infarct-reducing effect with an acceptable haemodynamic profile. BAY-58 may, therefore, be a promising candidate for the limitation of infarct size at reperfusion in man.


This study was supported by funds from Bayer Healthcare AG, Wuppertal, Germany.

Conflict of interest: J.-P.S. is currently a full-time employee of Bayer HealthCare.


View Abstract